Pharmacotherapy of childhood pneumonia

被引:5
作者
Nascimento-Carvalho, Cristiana M. [1 ]
机构
[1] Univ Fed Bahia, Sch Med, Dept Pediat, BR-40210630 Salvador, BA, Brazil
关键词
COMMUNITY-ACQUIRED PNEUMONIA; CASE-MANAGEMENT; CHILDREN; ETIOLOGY; RESISTANCE; PENICILLIN; MORTALITY; EPIDEMIOLOGY; ANTIBIOTICS; DIAGNOSIS;
D O I
10.1517/14656560903433714
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality among children under Syears. Although viral infections have been frequently recognized, death has been attributable to bacterial infections (especially due to Streptococcus pneumoniae). Areas covered in this review: In the past twenty years, childhood mortality due to CAP has been declining because of accessible health care and prompt antibiotic use. The basic options of antibiotics to treat children with CAP are presented. What the reader will gain: In daily practice, antibiotic prescription to treat childhood CAP is based on age and severity assessment. For those children aged less than 2 months, hospitalization and parenteral administration of ampicillin plus aminoglycoside or ampicillin plus third-generation cephalosporin is mandatory. For those patients aged 2 months and older with non-severe or severe CAP, the first option is amoxicillin or aqueous penicillin G, respectively; for very severe presentation, oxacillin and third-generation cephalosporin are recommended. If atypical bacteria infection is suspected, macrolide must be given in any age or severity group. Take home message: Few antibiotics are included in the guidelines to treat childhood CAP. The choice of which antibiotic should be given is based on clinical evaluation.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 46 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]   Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia [J].
Aspa, Javier ;
Rajas, Olga ;
de Castro, Felipe Rodriguez .
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (02) :229-241
[3]   Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial [J].
Atkinson, M. ;
Lakhanpaul, M. ;
Smyth, A. ;
Vyas, H. ;
Weston, V. ;
Sithole, J. ;
Owen, V. ;
Halliday, K. ;
Sammons, H. ;
Crane, J. ;
Guntupalli, N. ;
Walton, L. ;
Ninan, T. ;
Morjaria, A. ;
Stephenson, T. .
THORAX, 2007, 62 (12) :1102-1106
[4]   Case management of childhood pneumonia in developing countries [J].
Ayieko, Philip ;
English, Mike .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (05) :432-440
[5]   WHO estimates of the causes of death in children [J].
Bryce, J ;
Boschi-Pinto, C ;
Shibuya, K ;
Black, RE .
LANCET, 2005, 365 (9465) :1147-1152
[6]   Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia [J].
Cardoso, Maria Regina A. ;
Nascimento-Carvalho, Cristiana M. ;
Ferrero, Fernando ;
Berezin, Eltan N. ;
Ruvinsky, Raul ;
Camargos, Paulo A. M. ;
Sant'Anna, Clemax C. ;
Brandileone, Maria Cristina C. ;
March, Maria de Fatima P. ;
Feris-Iglesias, Jesus ;
Maggi, Ruben S. ;
Benguigui, Yehuda .
ARCHIVES OF DISEASE IN CHILDHOOD, 2008, 93 (03) :221-225
[7]   Management of community-acquired pneumonia in children [J].
Chetty K. ;
Thomson A.H. .
Pediatric Drugs, 2007, 9 (6) :401-411
[8]  
*CSLI, 2008, PERF STAND ANT SUSC
[9]   PARENTERAL-ORAL SWITCH IN THE MANAGEMENT OF PEDIATRIC PNEUMONIA [J].
DAGAN, R ;
SYROGIANNOPOULOS, G ;
ASHKENAZI, S ;
ENGELHARD, D ;
EINHORN, M ;
GATZOLAKARAVELLI, M ;
SHALIT, I ;
AMIR, J .
DRUGS, 1994, 47 :43-51
[10]  
Delport SD, 2002, SAMJ S AFR MED J, V92, P907